» Articles » PMID: 39140070

Lysineless HiBiT and NanoLuc Tagging Systems As Alternative Tools for Monitoring Targeted Protein Degradation

Overview
Specialty Chemistry
Date 2024 Aug 14
PMID 39140070
Authors
Affiliations
Soon will be listed here.
Abstract

Target protein degradation (TPD) has emerged as a revolutionary approach in drug discovery, leveraging the cell's intrinsic machinery to selectively degrade disease-associated proteins. Nanoluciferase (nLuc) fusion proteins and the NanoBiT technology offer two robust and sensitive screening platforms to monitor the subtle changes in protein abundance induced by TPD molecules. Despite these advantages, concerns have arisen regarding potential degradation artifacts introduced by tagging systems due to the presence of lysine residues on them, prompting the development of alternative tools. In this study, we introduce HiBiT-RR and nLuc, variants devoid of lysine residues, to mitigate such artifacts. Our findings demonstrate that HiBiT-RR maintains a similar sensitivity and binding affinity with the original HiBiT. Moreover, the comparison between nLuc and nLuc constructs reveals variations in degradation patterns induced by certain TPD molecules, emphasizing the importance of choosing appropriate tagging systems to ensure the reliability of experimental outcomes in studying protein degradation processes.

Citing Articles

Rapid and high-throughput screening of proteolysis targeting chimeras using a dual-reporter system expressing fluorescence protein and luciferase.

Meng S, Meng Y, Yang X, Yu W, Li B, Liu T BMC Biol. 2025; 23(1):51.

PMID: 39985000 PMC: 11846234. DOI: 10.1186/s12915-025-02153-7.


Luciferase complementation for cellular assays beyond protein-protein interactions.

Kawamura G, Ozawa T Anal Sci. 2025; .

PMID: 39966321 DOI: 10.1007/s44211-025-00730-y.


Four-color single-molecule imaging system for tracking GPCR dynamics with fluorescent HiBiT peptide.

Yoda T, Sako Y, Inoue A, Yanagawa M Biophys Physicobiol. 2025; 21(3):e210020.

PMID: 39802745 PMC: 11718171. DOI: 10.2142/biophysico.bppb-v21.0020.


Application of Fluorescence- and Bioluminescence-Based Biosensors in Cancer Drug Discovery.

Kelly T, Yang X Biosensors (Basel). 2024; 14(12).

PMID: 39727835 PMC: 11674898. DOI: 10.3390/bios14120570.


Suite of Biochemical and Cell-Based Assays for the Characterization of Kirsten Rat Sarcoma (KRAS) Inhibitors and Degraders.

Kidane M, Hoffman R, Wolfe-Demarco J, Huang T, Teng C, Samanta S ACS Pharmacol Transl Sci. 2024; 7(12):3921-3934.

PMID: 39698278 PMC: 11651172. DOI: 10.1021/acsptsci.4c00450.


References
1.
Zorba A, Nguyen C, Xu Y, Starr J, Borzilleri K, Smith J . Delineating the role of cooperativity in the design of potent PROTACs for BTK. Proc Natl Acad Sci U S A. 2018; 115(31):E7285-E7292. PMC: 6077745. DOI: 10.1073/pnas.1803662115. View

2.
Mullard A . Targeted protein degraders crowd into the clinic. Nat Rev Drug Discov. 2021; 20(4):247-250. DOI: 10.1038/d41573-021-00052-4. View

3.
Cardote T, Gadd M, Ciulli A . Crystal Structure of the Cul2-Rbx1-EloBC-VHL Ubiquitin Ligase Complex. Structure. 2017; 25(6):901-911.e3. PMC: 5462531. DOI: 10.1016/j.str.2017.04.009. View

4.
Garber K . The PROTAC gold rush. Nat Biotechnol. 2021; 40(1):12-16. DOI: 10.1038/s41587-021-01173-2. View

5.
Wang X, Qin Z, Li N, Jia M, Liu Q, Bai Y . Annual review of PROTAC degraders as anticancer agents in 2022. Eur J Med Chem. 2024; 267:116166. DOI: 10.1016/j.ejmech.2024.116166. View